Skip to content
Find a Provider
R J. White, M.D., Ph.D.

R J. White, M.D., Ph.D.

Pulmonary & Critical Care Medicine

5 out of 5 stars
248 Ratings
41 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 486-0869
Fax (585) 340-4009
Administrative (585) 275-4861

Locations

Mary Parkes Center for Asthma, Allergy & Pulmonary Care - Henrietta

Red Creek (Calkins Corporate Park)
400 Red Creek Drive, Suite 110
Rochester, NY 14623

(585) 486-0147 Get Directions

About Me

The overall goal of my clinical research and bench laboratory is to provide better care to patients with a rare disease of the lung blood vessels, pulmonary arterial hypertension (PAH). Our nationally accredited PHA Comprehensive Care Center provides evaluation and therapy for patients from all ove...
The overall goal of my clinical research and bench laboratory is to provide better care to patients with a rare disease of the lung blood vessels, pulmonary arterial hypertension (PAH). Our nationally accredited PHA Comprehensive Care Center provides evaluation and therapy for patients from all over New York and central PA, and we use the full complement of approved PAH therapies. We also contribute actively to clinical research in hopes of better therapies with drugs that are already available and those yet to be approved. I serve as leadership on steering committees and DSMB for global clinical trials in this deadly disease.

In my laboratory, we do experiments in animals and cells in an attempt to discover entirely new ways to treat this deadly disease.

Because echocardiograms often estimate pulmonary hypertension in patients with obstructive sleep apnea and heart failure, much of my clinical practice and expertise is focused in these two common problems.

The URMC Pulmonary Hypertension group also includes my partner Dan Lachant, MD; three full time RN's, Karen Frutiger, Ali Theuer and new comer Cyndi MacDonald; a full time administrator, Jocelyn Dixon; two research technicians, Deb Haight and Jackie Bruno; and a post-doctoral research associate, Allison Light.

Certified Specialties

Pulmonary Disease - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Pulmonary Diseases and Critical Care (SMD)

Professor - Department of Pediatrics, Cardiology (SMD) - Joint

Professor - Department of Pharmacology and Physiology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Pulmonary and Critical Care Medicine, University of Rochester Medical Center. 2000 - 2003

Residency, Internal Medicine, University of Rochester Medical Center. 1998 - 2000

Internship, Internal Medicine, University of Rochester Medical Center. 1997 - 1998

Education

MD | University of Pittsburgh School of Medicine. 1997

Awards

Parker B. Francis Fellowship in Pulmonary Biology, Francis Family Foundation 2005 - 2007

Buswell Fellowship, Department of Medicine, University of Rochester SMD 2003 - 2005

NIH Training Grant Multi-Disciplinary Training & Pulmonary Research, University of Rochester SMD 2001 - 2004

Alpha Omega Alpha, University of Pittsburgh 1996

NIH Medical Scientist Training Program, University of Pittsburgh 1990 - 1997

Phi Beta Kappa, Ohio State University 1990

Research

The University of Rochester is a nationally accredited PHA Comprehensive Care Center, and we provide evaluations for patients with echo estimated pulmonary hypertension. We take care of ~300 patients with WHO Group 1 classified Pulmonary Arterial Hypertension. I was a lead enroller and study autho...
The University of Rochester is a nationally accredited PHA Comprehensive Care Center, and we provide evaluations for patients with echo estimated pulmonary hypertension. We take care of ~300 patients with WHO Group 1 classified Pulmonary Arterial Hypertension. I was a lead enroller and study author in the labeling trials for tadalafil (PHIRST), oral treprostinil (Freedom-M), and the initial combination Ambition study. I chair the Freedom-EV steering committee and am leading the ongoing global development efforts for oral treprostinil in WHO Group 1. We participated actively in the Reveal registry, and I am associate medical director for Bill Nichols' NIH funded PAH Biobank. We are the lead nationwide enrollers for the NIH funded study of rituxan in scleroderma PAH, and we are making active contributions to Reata's studies of bardoxolone. We use subcutaneous treprostinil (Remodulin, more than 150 patients over the years), inhaled Tyvaso, ambrisentan, tadalafil, macitentan, selexipag, and riociguat in combinations best tailored to a particular patient's needs. We provide a strong link to surgical centers at Massachusetts General and Allegheny General for our patients with chronic thromboembolic pulmonary hypertension.

I am grateful for the opportunity to serve as steering committee leadership in drug development projects with United Therapeutics (oral treprostinil) and PhaseBio (VIP analogue PB1046). I also serve as a consultant providing development advice to Reata, Gilead, Bayer, and Celtaxsys. I chair the DSMB for the first randomized, placebo-controlled trial of genetically-modified, endothelial progenitor cells led by colleagues in Canada (sponsor, Northern Therapeutics).

The overall goal of my bench laboratory is to do better preclinical testing of potential novel treatment options for pulmonary arterial hypertension. Our current approach is with a rat model that recapitulates the histopathology, severe hemodynamic alterations, and right ventricular heart failure seen in advanced human disease. This rat model employs pneumonectomy (promotes contralateral lung growth) and endothelial injury (low dose monocrotaline) to cause lethal pulmonary hypertension in about 4 weeks. Our animals die earlier with a more severe phenotype, and we presented the first report of proliferative, plexiform-like lesions in 2004. We have developed a novel CT angiography to assess for vascular pruning during disease progression, and we have become expert at evaluating RV size and function with echo. We have also utilized telemetry techniques to measure pressure in awake, behaving animals. Our main recent contribution has been to establish a model severe enough that we can test new therapy approaches in animals treated with today's FDA approved agents. We believe that this sort of preclinical testing will provide the best evidence to move compounds into the clinic. Deb Haight, LVT, leads the lab work.

We hypothesize that tissue factor (the membrane bound glycoprotein which initiates coagulation) is an important contributor to disease progression, and we are actively testing small molecule inhibitors of tissue factor and thrombin as novel therapies in this devastating disease.

Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH),A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

Lead Researcher: R James White III

Seralutinib is an inhaled medication for PAH. Participants with PAH age 18-75 and a BMI of 17-40 may be eligible to participate. Participants will be randomized to either placebo or drug. The duration of the study is up to a maximum of 48 weeks.

Patents

Treatment of Pulmonary Hypertension Using An Agent that Inhibits a Tissue Factor Pathway

Issue date: October 22, 2013

Treatment of Pulmonary Hypertension Using an Agent that Inhibits a Tissue Factor Pathway

Issue date: July 15, 2015

Treatment of Pulmonary Hypertension Using An Agent that Inhibits a Tissue Factor Pathway

Issue date: July 15, 2015

Treatment of Pulmonary Hypertension Using An Agent that Inhibits a Tissue Factor Pathway

Issue date: July 15, 2015

Treatment of Pulmonary Hypertension Using An Agent that Inhibits a Tissue Factor Pathway

Issue date: July 15, 2015

Publications

Journal Articles

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients.

Rahaghi FF, Humbert M, Hoeper MM, White RJ, Frantz RP, Hassoun PM, Hemnes AR, Kawut SM, McLaughlin VV, Meszaros G, Mol PGM, Nathan SD, Psotka MA, Rahaghi FN, Sitbon O, Stockbridge N, Weatherald J, Zannad F, Sahay S

The Lancet. Respiratory medicine.. 2025 February 20 Epub 02/20/2025.

Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan.

Vizza CD, Klok R, Harley J, Small M, Scott M, Lautsch D, White RJ

Advances in therapy.. 2025 January 42 (1):193-215. Epub 11/04/2024.

Heart Rate Variability in Pulmonary Arterial Hypertension.

Gyawali B, Roto D, Lachant M, White RJ, Lachant D

Pulmonary circulation.. 2025 January 15 (1):e70048. Epub 02/08/2025.

Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus.

Manzi G, Benza RL, Argiento P, Casu G, Corda M, Correale M, D'Alto M, Galgano G, Garascia A, Ghio S, Gomberg-Maitland M, Mulé M, Paciocco G, Papa S, Prati D, Preston IR, Raineri C, Romeo E, Scelsi L, Stolfo D, Vitulo P, White RJ, Badagliacca R, Vizza CD

Vascular pharmacology.. 2024 December 157 :107432. Epub 09/10/2024.

Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).

Petrow E, Feng C, Frazer-Abel A, Marangoni RG, Lutz K, Nichols WC, Holers VM, Ritchlin C, White RJ, Korman BD

Seminars in arthritis and rheumatism.. 2024 December 69 :152554. Epub 09/13/2024.

Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.

White RJ, El-Kersh K, Rosenkranz S, Franco V, Vizza CD, Badagliacca R, Pepke-Zaba J, Elwing J, Argula RG, Shapiro S, Kim H, Seaman S, Shen E, Das M, Broderick M, McLaughlin V

Chest.. 2024 November 30 Epub 11/30/2024.

Health-related quality of life and symptom concordance between patients and physicians in pulmonary arterial hypertension in the United States, Europe, and Japan.

White RJ, Vizza D, Klok R, Lautsch D, Harley J, Small M

Respiratory medicine.. 2024 November 18 :107869. Epub 11/18/2024.

Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.

Benza RL, Simonneau G, Ghofrani HA, Corris PA, Langleben D, Rosenkranz S, White RJ, Cheng CC, Campos FTAF, Kim HK, Souza R, Chang M, Rahner C, Meier C, Hoeper MM

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.. 2024 October 43 (10):1756-1760. Epub 06/07/2024.

Electronically delivered rehabilitation after acute pulmonary embolism is safe and improves quality of life.

Lachant D, Haight D, Roto D, Williams A, Norton K, White RJ

The European respiratory journal.. 2024 September 64 (3)Epub 09/05/2024.

Cardiac effort and 6-min walk distance correlate with stroke volume measured by cardiac magnetic resonance imaging.

Lachant DJ, Lachant MD, Haight D, White RJ

Pulmonary circulation.. 2024 April 14 (2):e12355. Epub 04/01/2024.

Risk scores as a surrogate in pulmonary arterial hypertension: a different lens.

White RJ, Lachant DJ, Benza RL

The Lancet. Respiratory medicine.. 2024 March 12 (3):e9-e10. Epub 1900 01 01.

Risk Stratification in Pulmonary Arterial Hypertension: Perhaps Simple Is Not Best?

Fauvel C, White RJ, Vanderpool RR, Badagliacca R, Tobore T, Rahman M, Vizza CD, Lin S, Everett AD, Visovatti SH, Benza RL

Chest.. 2024 February 165 (2):431-436. Epub 09/12/2023.

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension.

Grünig E, Rahaghi F, Elwing J, Vizza CD, Pepke-Zaba J, Shen J, Yao H, Hage A, Rosenkranz S, Vonk M, Balasubramanian V, Yuanhua Y, Yu Z, Lordan J, Cadaret L, Grover R, Ousmanou A, Seaman S, Deng C, Broderick M, White RJ,

Advances in therapy.. 2024 February 41 (2):618-637. Epub 12/06/2023.

Regional Variation in Pulmonary Arterial Hypertension in the United States: The Pulmonary Hypertension Association Registry.

Fling C, De Marco T, Kime NA, Lammi MR, Oppegard LJ, Ryan JJ, Ventetuolo CE, White RJ, Zamanian RT, Leary PJ,

Annals of the American Thoracic Society.. 2023 December 20 (12):1718-1725. Epub 1900 01 01.

Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension.

Lachant D, Light A, Lachant M, Annis J, Hemnes A, Brittain E, James White R

Pulmonary circulation.. 2023 July 13 (3):e12285. Epub 09/10/2023.

Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS.

Bernstein DN, Cliburn JA, Lachant DJ, White RJ, Hammert WC

Hand : official journal of the American Association for Hand Surgery.. 2023 January 18 (1):15-21. Epub 03/31/2021.

Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in Pulmonary Arterial Hypertension.

Lachant D, Kennedy E, Derenze B, Light A, Lachant M, White RJ

Chest.. 2022 December 162 (6):1340-1348. Epub 06/28/2022.

Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV.

Benza RL, Gomberg-Maitland M, Farber HW, Vizza CD, Broderick M, Holdstock L, Nelsen AC, Deng C, Rao Y, White RJ

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.. 2022 November 41 (11):1572-1580. Epub 08/15/2022.

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry.

Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T, Frantz RP, Hemnes A, Mathai SC, Rosenzweig EB, Ryan JJ, Thenappan T,

Journal of the American Heart Association.. 2022 May 311 (9):e024969. Epub 04/27/2022.

Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?

Vizza CD, Lang IM, Badagliacca R, Benza RL, Rosenkranz S, White RJ, Adir Y, Andreassen AK, Balasubramanian V, Bartolome S, Blanco I, Bourge RC, Carlsen J, Conde Camacho RE, D'Alto M, Farber HW, Frantz RP, Ford HJ, Ghio S, Gomberg-Maitland M, Naeije R, Orfanos SE, Oudiz RJ, Perrone SV, Shlobin OA, Simon MA, Torres F, Wang KY, Yacoub MH, Liu Y, Golden G, Matsubara H

American journal of respiratory and critical care medicine.. 2022 April 1205 (7):751-760. Epub 1900 01 01.

Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.

Rahaghi FF, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, King C, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White RJ, Hill NS

Pulmonary circulation.. 2022 April 12 (2):e12055. Epub 04/07/2022.

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension.

Khan A, White RJ, Meyer G, Pulido Zamudio TR, Jerjes-Sanchez C, Johnson D, Grover R, Broderick M, Ousmanou A, Holdstock L, Michelakis E

Respiratory medicine.. 2022 March 193 :106744. Epub 01/19/2022.

Comparison of chest- and wrist-based actigraphy in pulmonary arterial hypertension.

Lachant D, Light A, Hannon K, Abbas F, Lachant M, White RJ

European heart journal. Digital health.. 2022 March 3 (1):90-97. Epub 11/02/2021.

Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.

Rosenkranz S, Feldman J, McLaughlin VV, Rischard F, Lange TJ, White RJ, Peacock AJ, Gerhardt F, Ebrahimi R, Brooks G, Satler C, Frantz RP,

The Lancet. Respiratory medicine.. 2022 January 10 (1):35-46. Epub 08/20/2021.

Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension.

Wang S, Zhu G, Jiang D, Rhen J, Li X, Liu H, Lyu Y, Tsai P, Rose Y, Nguyen T, White RJ, Pryhuber GS, Mariani TJ, Li C, Mohan A, Xu Y, Pang J

Hypertension.. 2022 January 79 (1):79-92. Epub 11/05/2021.

An untapped resource: characteristics of thrombus recovered from intermediate or high risk pulmonary embolus patients.

Newcomb G, Wilson BL, White RJ, Goldman B, Lachant NA, Lachant DJ

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.. 2022 57 :107392. Epub 10/27/2021.

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension.

Arevalo C, White RJ, Lachant D

Respiratory medicine case reports.. 2022 37 :101646. Epub 04/09/2022.

Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience.

Arevalo C, White RJ, Le T, Lachant D

Respiratory medicine.. 2021 November 188 :106596. Epub 09/04/2021.

Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza.

Lachant D, Roto D, Rappaport S, Prasad P, Lachant N, White RJ

Thrombosis research.. 2021 September 205 :40-43. Epub 07/03/2021.

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.

Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, Keyes-Elstein L, D'Aveta C, Spychala M, White RJ, Hassoun PM, Torres F, Sweatt AJ, Molitor JA, Khanna D, Maecker H, Welch B, Goldmuntz E, Nicolls MR,

American journal of respiratory and critical care medicine.. 2021 July 15204 (2):209-221. Epub 1900 01 01.

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.

Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G,

The Lancet. Respiratory medicine.. 2021 June 9 (6):573-584. Epub 03/24/2021.

Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, Klinger J, Lammi M, Mazimba S, Sager J, Shlobin O, Simon M, Thenappan T, Grinnan D, Ventetuolo C, Al-Naamani N,

American journal of respiratory and critical care medicine.. 2021 March 15203 (6):761-764. Epub 1900 01 01.

Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli.

Lachant DJ, Bach C, Fe A, White RJ, Lachant NA

ERJ open research.. 2021 January 7 (1)Epub 02/01/2021.

Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Bell RD, White RJ, Garcia-Hernandez ML, Wu E, Rahimi H, Marangoni RG, Slattery P, Duemmel S, Nuzzo M, Huertas N, Yee M, O'Reilly MA, Morrell C, Ritchlin CT, Schwarz EM, Korman BD

Arthritis & rheumatology.. 2020 October 72 (10):1759-1770. Epub 08/20/2020.

Endothelial-to-Mesenchymal Transition and Inflammation Play Key Roles in Cyclophilin A-Induced Pulmonary Arterial Hypertension.

Xue C, Senchanthisai S, Sowden M, Pang J, White J, Berk BC

Hypertension.. 2020 October 76 (4):1113-1123. Epub 08/24/2020.

Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection.

Lachant DJ, Lachant NA, Kouides P, Rappaport S, Prasad P, White RJ

Journal of thrombosis and haemostasis : JTH.. 2020 October 18 (10):2640-2645. Epub 08/24/2020.

Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry.

DesJardin JT, Kolaitis NA, Kime N, Kronmal RA, Benza RL, Elwing JM, Lammi MR, McConnell JW, Presberg KW, Sager JS, Shlobin OA, De Marco T,

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.. 2020 September 39 (9):945-953. Epub 05/16/2020.

Selexipag Use in Clinical Practice: Mind the Gap.

White RJ, Lachant DJ

Chest.. 2020 April 157 (4):761-763. Epub 1900 01 01.

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.

White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF,

American journal of respiratory and critical care medicine.. 2020 March 15201 (6):707-717. Epub 1900 01 01.

Heart Rate Expenditure Correlates with Right Ventricular Function.

Lachant DJ, Light AN, Mackin ML, Schwartz RG, White RJ

Annals of the American Thoracic Society.. 2020 March 17 (3):372-375. Epub 1900 01 01.

Combination of treprostinil with sympathectomy and vascular reconstruction to treat recurrent digital ulcer disease.

Lemay M, Korman B, Hammert W, White RJ, Lachant D

Clinical and experimental rheumatology.. 2020 38 Suppl 125 (3):176-177. Epub 04/15/2020.

Clinical trial design in phase 2 and 3 trials for pulmonary hypertension.

Nikkho S, Fernandes P, White RJ, Deng CC, Farber HW, Corris PA

Pulmonary circulation.. 2020 10 (4):2045894020941491. Epub 07/20/2020.

Heart rate monitoring improves clinical assessment during 6-min walk.

Lachant DJ, Light A, Offen M, Adams J, White RJ

Pulmonary circulation.. 2020 10 (4):2045894020972572. Epub 12/09/2020.

Predicting hospital-onset using patient mobility data: A network approach.

Bush K, Barbosa H, Farooq S, Weisenthal SJ, Trayhan M, White RJ, Noyes EI, Ghoshal G, Zand MS

Infection control and hospital epidemiology.. 2019 December 40 (12):1380-1386. Epub 10/28/2019.

Combination therapy improves vascular volume in female rats with pulmonary hypertension.

Lachant DJ, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ

American journal of physiology. Lung cellular and molecular physiology.. 2019 October 1317 (4):L445-L455. Epub 07/19/2019.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE

Respiratory research.. 2019 September 1220 (1):208. Epub 09/12/2019.

EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics.

White RJ, Parikh K, Allen R, Feldman J, Jerjez-Sanchez C, Pan L, Keogh AM, Vizza CD, Shapiro SM, Gordon K, Broderick M, Bartolome S

Pulmonary circulation.. 2019 July 1010 (4):2045894019866335. Epub 07/10/2019.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, Ross RVM, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Noordegraaf AV, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR, , ,

The Lancet. Respiratory medicine.. 2019 March 7 (3):227-238. Epub 12/05/2018.

Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.

Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, White RJ

Journal of managed care & specialty pharmacy.. 2018 August 24 (8):834-842. Epub 02/13/2018.

New Therapeutic Approaches in Pulmonary Arterial Hypertension: The Pantheon Is Getting Crowded.

White RJ, Wilkins MR

Circulation.. 2018 May 29137 (22):2390-2392. Epub 1900 01 01.

Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats.

Lachant DJ, Meoli DF, Haight D, Lyons JA, Swarthout RF, White RJ

Experimental lung research.. 2018 February 44 (1):51-61. Epub 01/30/2018.

8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain.

Light A, Heininger A, Wessman K, Frutiger K, White RJ

Pain medicine : the official journal of the American Academy of Pain Medicine.. 2017 December 118 (12):2515-2517. Epub 1900 01 01.

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation.

Rahaghi FF, Feldman JP, Allen RP, Tapson V, Safdar Z, Balasubramanian VP, Shapiro S, Mathier MA, Elwing JM, Chakinala MM, White RJ

Pulmonary circulation.. 2017 March 7 (1):167-174. Epub 03/21/2017.

Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.

Chakinala MM, Feldman JP, Rischard F, Mathier M, Broderick M, Leedom N, Laliberte K, White RJ

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.. 2017 February 36 (2):193-201. Epub 06/24/2016.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JH, Blair C, Rubin LJ, Vachiery JL

The Lancet. Respiratory medicine.. 2016 November 4 (11):894-901. Epub 10/11/2016.

Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data.

White RJ, Rao Y

American journal of respiratory and critical care medicine.. 2016 June 15193 (12):1434-6. Epub 1900 01 01.

Estrogen: Friend or Foe in Pulmonary Hypertension?

White RJ

American journal of respiratory and critical care medicine.. 2016 May 15193 (10):1084-6. Epub 1900 01 01.

Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis.

Crosby A, Soon E, Jones FM, Southwood MR, Haghighat L, Toshner MR, Raine T, Horan I, Yang P, Moore S, Ferrer E, Wright P, Ormiston ML, White RJ, Haight DA, Dunne DW, Morrell NW

American journal of respiratory and critical care medicine.. 2015 December 1192 (11):1355-65. Epub 1900 01 01.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ,

The New England journal of medicine.. 2015 August 27373 (9):834-44. Epub 1900 01 01.

Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease.

Schlosser K, McIntyre LA, White RJ, Stewart DJ

PloS one.. 2015 10 (5):e0127443. Epub 05/26/2015.

Thrombosis, platelets, microparticles and PAH: more than a clot.

Lannan KL, Phipps RP, White RJ

Drug discovery today.. 2014 August 19 (8):1230-5. Epub 04/18/2014.

Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed.

White RJ, Lannan KL, Phipps RP

Drug discovery today.. 2014 August 19 (8):1226-9. Epub 04/21/2014.

Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics.

White RJ, Levin Y, Wessman K, Heininger A, Frutiger K

Pulmonary circulation.. 2013 September 3 (3):611-21. Epub 11/18/2013.

Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.

White RJ, Torres F, Allen R, Jerjes C, Pulido T, Yehle D, Howell M, Laliberte K, Marier J, Tapson VF

Journal of cardiovascular pharmacology.. 2013 June 61 (6):474-81. Epub 1900 01 01.

Understanding the low penetrance of bone morphogenetic protein receptor 2 gene mutations: another needle in the haystack.

White RJ, Morrell NW

Circulation.. 2012 October 9126 (15):1818-20. Epub 1900 01 01.

Hip fracture in a patient with severe pulmonary hypertension.

Friedman SM, White RJ, Finkelstein SM, Kellam J, Allen EF, Sip AK, Stanton R

Geriatric orthopaedic surgery & rehabilitation.. 2012 September 3 (3):135-40. Epub 1900 01 01.

Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.

Ferrantino M, White RJ

Expert opinion on pharmacotherapy.. 2011 November 12 (16):2583-93. Epub 1900 01 01.

Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice.

Yee M, White RJ, Awad HA, Bates WA, McGrath-Morrow SA, O'Reilly MA

The American journal of pathology.. 2011 June 178 (6):2601-10. Epub 05/06/2011.

Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.

Levin YD, White RJ

Drugs of today.. 2011 February 47 (2):145-56. Epub 1900 01 01.

Endothelin-1 induces pulmonary but not aortic smooth muscle cell migration by activating ERK1/2 MAP kinase.

Meoli DF, White RJ

Canadian journal of physiology and pharmacology.. 2010 August 88 (8):830-9. Epub 1900 01 01.

Rationale for the judicious use of placebos in PAH trials.

White RJ, Hiremath J

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.. 2010 July 29 (7):826-7. Epub 05/14/2010.

Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II.

Meoli DF, White RJ

American journal of physiology. Lung cellular and molecular physiology.. 2009 October 297 (4):L706-14. Epub 07/31/2009.

G-protein-coupled receptor kinase interacting protein-1 is required for pulmonary vascular development.

Pang J, Hoefen R, Pryhuber GS, Wang J, Yin G, White RJ, Xu X, O'Dell MR, Mohan A, Michaloski H, Massett MP, Yan C, Berk BC

Circulation.. 2009 March 24119 (11):1524-32. Epub 03/09/2009.

Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.

Gough MS, White RJ

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.. 2009 January 15 (1):30-6. Epub 1900 01 01.

Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.

White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB

American journal of physiology. Lung cellular and molecular physiology.. 2007 September 293 (3):L583-90. Epub 06/22/2007.

Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease.

White RJ, Galaria II, Harvey J, Blaxall BC, Cool CD, Taubman MB

Chest.. 2005 December 128 (6 Suppl):612S-613S. Epub 1900 01 01.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Concern the care provider showed for your questions or worries

4.9 stars

Care provider's efforts to include you in decisions about your care

4.9 stars

Explanations the care provider gave you about your problem or condition

4.9 stars

Likelihood of recommending this care provider to others

4.9 stars

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.9 stars

Patient Comments

4.8 stars

Great bedside manner. Dr. White doesn't talk down to you but more like a friend who happens to be a specialist

Jun 16, 2024

5.0 stars

Dr. WHITE is the most caring, most thorough, the most understanding Dr I've ever met. His notes are impeccable. All my other Drs thought the notes were impressive!! Dr White should be the Gold standard by which all Drs are measured against!! He's a great man!!

Apr 27, 2024

5.0 stars

I'd give my doctor an excellent rating, but very good is the highest the survey allows.

Mar 17, 2024

5.0 stars

A great provider who answered my questions and took the time to know me

Jan 09, 2024

Dr. White was very good and helpful

Dec 18, 2023

Had already read my record prior to visit. Addressed me at a level appropriate to my background and level of knowledge. Gave clear answers to my concerns and my goals, respecting my patient autonomy. Came up with a clear plan of care.

Dec 12, 2023

5.0 stars

I was particularly impressed by Dr. White. It was an amazing sense of being heard, and he was able to enlighten us to our current condition in a manner that was previously misses, helping us extremely to understand the condition and also worked through the prescription cost shock and gave insights for understanding that as well. I've not had a doctor visit in quite some time where I was so impressed. He really stepped up for us and I hope he knows he made an impact and that we appreciate it very much!

Nov 30, 2023

5.0 stars

Why can't all my doctor be like him. Caring, professional, knowledgeable, the best! What I needed!

Nov 02, 2023

Dr White answered any question I had.

Sep 05, 2023

5.0 stars

Dr. White is a wonderful doctor! He treated us with kindness and respect. You can tell he cares for his patients.

Sep 04, 2023